CD73+ regulatory T cells contribute to

adenosine-mediated resolution of acute lung injury by Ehrentraut, Heidi et al.
The FASEB Journal • Research Communication
CD73 regulatory T cells contribute to
adenosine-mediated resolution of acute lung injury
Heidi Ehrentraut,*,‡ Eric T. Clambey,* Eoin N. McNamee,* Kelley S. Brodsky,*
Stefan F. Ehrentraut,†,‡ Jens M. Poth,*,‡ Ann K. Riegel,* Joseph A. Westrich,*
Sean P. Colgan,† and Holger K. Eltzschig*,1
*Department of Anesthesiology and †Department of Medicine, Mucosal Inflammation Program,
University of Colorado School of Medicine, Aurora, Colorado, USA; and ‡Department of
Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
ABSTRACT Acute lung injury (ALI) is characterized
by alveolar injury and uncontrolled inflammation. Since
most cases of ALI resolve spontaneously, understand-
ing the endogenous mechanisms that promote ALI
resolution is important to developing effective thera-
pies. Previous studies have implicated extracellular
adenosine signaling in tissue adaptation and wound
healing. Therefore, we hypothesized a functional con-
tribution for the endogenous production of adenosine
during ALI resolution. As a model, we administered
intratracheal LPS and observed peak lung injury at 3 d,
with resolution by d 14. Treatment with pegylated
adenosine-deaminase to enhance extracellular adeno-
sine breakdown revealed impaired ALI resolution. Sim-
ilarly, genetic deletion of cd73, the pacemaker for
extracellular adenosine generation, was associated with
increased mortality (0% wild-type and 40% in cd73/
mice; P<0.05) and failure to resolve ALI adequately.
Studies of inflammatory cell trafficking into the lungs
during ALI resolution revealed that regulatory T cells
(Tregs) express the highest levels of CD73. While Treg
numbers in cd73/ mice were similar to controls,
cd73-deficient Tregs had attenuated immunosuppres-
sive functions. Moreover, adoptive transfer of cd73-
deficient Tregs into Rag/ mice emulated the ob-
served phenotype in cd73/ mice, while transfer of
wild-type Tregs was associated with normal ALI resolu-
tion. Together, these studies implicate CD73-dependent
adenosine generation in Tregs in promoting ALI resolu-
tion.—Ehrentraut, H., Clambey, E. T., McNamee, E. N.,
Brodsky, K. S., Ehrentraut, S. F., Poth, J. M., Riegel, A. K.,
Westrich, J. A., Colgan, S. P., Eltzschig, H. K. CD73
regulatory T cells contribute to adenosine-mediated
resolution of acute lung injury. FASEB J. 27,
2207–2219 (2013). www.fasebj.org
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Acute lung injury (ALI) is characterized by acute
hypoxemic respiratory failure in the setting of noncar-
diogenic pulmonary edema with a significant contribu-
tion to morbidity and mortality of critically ill patients
(1, 2). In fact, ALI mortality ranges between 35 and
60%, and 200,000 patients develop ALI annually in
the United States, leading to 75,000 deaths (3). Among
the hallmarks of ALI is massive accumulation of inflam-
matory cells into different compartments of the lungs
in conjunction with cytokine release and inflammatory
activation of recruited or resident cells (4). Other
characteristics include epithelial injury, causing disrup-
tion of the alveolar-capillary barrier function, resulting
in extensive pulmonary edema and attenuated gas
exchange. Previous research studies have focused
mainly on the onset phase of ALI and have proposed
strategies to prevent ALI development (4–7). However,
in many instances, ALI is not recognized in its early
onset stage. Indeed, clinicians are more frequently
faced with the challenge of having to treat patients that
have fully developed ALI, including the presence of
inflammatory cells within the lungs, exposure to toxins
produced by microorganisms, epithelial injury, and
pulmonary edema. At this stage, the inflamed mucosal
tissues follow a decision pathway to either resolve or to
proceed toward an uncontrolled inflammatory re-
sponse that often leads to death. In the present studies,
we hypothesize the existence of endogenous protective
molecular pathways at the interface between innate and
adaptive immunity that can be targeted to promote ALI
resolution.
Extracellular adenosine is an endogenously pro-
duced signaling molecule (2) that has been implicated
previously in attenuating inflammation during inflam-
matory diseases (5, 7–12), hypoxia (1, 13–17), or ische-
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mia and reperfusion injury (16–20). Adenosine recep-
tors 2a and 2b (A2aR and A2bR) are critical for the
limitation of inflammatory responses. Genetic models
and pharmacological inhibition have been shown to
augment inflammation in A2aR- or A2bR-signaling-
deficient mice (21, 22). However, their functional role
during the resolution phase of ALI remains unclear.
During inflammatory conditions, extracellular adeno-
sine stems predominantly from the breakdown of pre-
cursor nucleotides, such as ATP, ADP, and AMP (2, 23).
This process is controlled by a set of enzymes that
regulate extracellular nucleotide phosphohydrolysis.
The pacemaker enzyme for the extracellular genera-
tion of adenosine is 5=-ectonucleotidase (CD73), an
ectoenzyme that converts extracellular AMP to adeno-
sine and thereby controls the final step for the libera-
tion of adenosine (24–27). In vitro evidence confirmed
for the first time that regulatory T cells (Tregs) express
high amounts of cd73 and generate adenosine (28),
thereby acting inhibitory on activated A2aR-expressing
effector T cells (29).
To address the functional role of extracellular aden-
osine during the resolution phase of ALI, we exposed
mice to ALI induced by intratracheal installation of
lipopolysaccharide (LPS) and allowed mice to recover
over a time period of 14 d. Subsequently, we combined
genetic and pharmacologic approaches to alter extracel-
lular generation of adenosine and thereby its signaling
effects. These studies pointed us toward a functional role
of extracellular adenosine generation during ALI resolu-
tion and implicate CD73 Tregs in adenosine-mediated
ALI resolution.
MATERIALS AND METHODS
Experimental animals
Cd73/ (C57BL/6J) and cd73/ mice were bred in house.
Cd73/ mice were generated on a BL6 strain as described
previously (6, 7, 24, 30–32). B6.Rag1/ mice (B6.129S7-
Rag1tm1Mom) were obtained from Jackson Laboratory (Bar
Harbor, ME, USA). Mice were bred and maintained in
accordance with the recommendations of the U.S. National
Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals. Experimental protocols were approved
by the Institutional Review Board at the University of Colo-
rado Denver and were in accordance with the Protection of
Animals and the NIH guidelines for the use of live animals.
ALI model
Age (8–12 wk old) and weight-matched male cd73/ and
cd73/ mice were anesthetized with pentobarbital (70 mg/
kg) before the procedure. LPS (Escherichia coli 0111:B4,
L4391; Sigma, St. Louis, MO, USA; 3.75 g/g body weight
unless otherwise indicated) or saline as control was adminis-
tered intratracheally via a 22-gauge catheter (33). Within up
to 14 d post-LPS exposure, weight loss and recovery were
recorded.
Treatment with pegylated adenosine deaminase (PEG-ADA)
to dampen extracellular adenosine production and signaling
BL6 mice were injected intraperitoneally with 10 U PEG-ADA
3 d before LPS or saline instillation and immediately after
intratracheal treatment (see Fig. 1A). Polyethylene glycol-
modified ADA possesses a prolonged circulatory time due to
reduced renal clearance (34). One unit of PEG-ADA is
defined as the amount of enzyme necessary to convert 1 mol
of adenosine to inosine per minute at 25°C (35). Animals
incorporated in the weight loss recording groups received a
third dose 7 d post-LPS application. A total volume of 100 l
was injected, and saline served as control treatment.
5=-Nucleotidase (5=-NT) reconstitution
5=-NT from Crotalus atrox venom (Enzo Life Sciences, Farm-
ingdale, NY, USA) was diluted in saline to a final concentra-
tion of 2 U 5=-NT/100 l as done previously (10). Experimen-
tal animals received an intraperitoneal injection of 2 U 5=-NT
or an equal volume of vehicle immediately after LPS treat-
ment. Injection was repeated daily.
Tissue harvest
At indicated time points, mice were anesthetized and killed by
exsanguination. Bronchoalveolar lavage fluid (BALF) was
obtained after lavaging the lung with 3 1 ml saline. Cell-free
BALF supernatant for ELISA studies was snap-frozen after
centrifugation at 1000 g for 5 min at 4°C. Pulmonary tissue
was flushed with 10 ml saline via the right ventricle, snap-
frozen in liquid nitrogen, and stored at 80°C.
RNA isolation and real-time PCR
Total RNA was extracted from tissue by Trizol, followed by
cDNA synthesis using iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA) according to the manufacturer’s instructions.
Quantitative reverse transcriptase PCR (qPCR; ABI 7900HT;
Applied Biosystems, Carlsbad, CA, USA) was performed to
measure relative mRNA levels for various transcripts, with
Power SYBR Green PCR Master Mix (Applied Biosystems),
containing 1 M sense and 1 M antisense primers. Results
were evaluated with the 2Ct method using -actin as an
internal control.
Primers for real-time RT-PCR
Real-time RT-PCR was performed with the following murine
Quantitect Primer Assays (Qiagen, Valencia, CA, USA): -actin
(QT01136772), TNF- (QT00104006), IL-1 (QT01048355),
and IL-6 (QT00098875).
Leukocyte counts of BALF
BAL samples were mixed gently before diluting 50 l of BALF
with 50 l of trypan blue (1:5 in 1 PBS) for viable cell
counts. Then, 20 l of diluted cell sample was pipetted on a
cellometer cell counting chamber. Leukocytes were automat-
ically counted using a Cellometer Auto T4 (Nexcelom Biosci-
ence, Lawrence, MA, USA).
Measurement of BALF albumin content
Albumin content of BALF supernatants was measured with a
mouse albumin ELISA Quantitation Set (Bethyl Laboratories,
Montgomery, TX, USA) according to the manufacturer’s
instructions. Samples were diluted 1:10,000.
Myeloperoxidase (MPO) assay
MPO is rapidly released by activated polymorphonuclear
neutrophils, monocytes and macrophages. Tissue was homog-
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enized and lysed in ice-cold lysis buffer (200 mM NaCl, 5 mM
EDTA, 10 mM Tris, 10% glycerol, 1 mM PMSF, 1 g/ml
leupeptide, and 28 g/ml aprotinine, pH 7.4). Tissue sam-
ples were measured with a mouse MPO ELISA kit (Hycult
Biotech, Plymouth Meeting, PA, USA). MPO levels were
normalized to protein concentrations afterward.
Cytokine protein levels
Concentrations of TNF- and IL-10 were measured in BALF
or cell culture supernatant. All mediators were determined
using commercially available ELISA kits for mouse (TNF-
DuoSet ELISA development system, R&D Systems, Minneap-
olis, MN, USA; IL-10 ELISA Ready-SET GO!, eBioscience, San
Diego, CA, USA) according to the manufacturer’s instruc-
tions.
Lung histology and lung injury scoring
To examine the amount of cellular infiltrates as well as the
tissue integrity in histological slices of pulmonary tissue, mice
were killed by a pentobarbital overdose, followed by exsan-
guination. Lungs were inflated with 0.7 ml of 10% formalin
and fixed in 10% formalin solution overnight. After auto-
mated dehydration through a graded ethyl alcohol series,
tissue was embedded in paraffin, sectioned at 5 m, and
stained with hematoxylin and eosin (H&E). Two investigators
blinded to group assignments analyzed the samples and
determined the levels of lung injury according to semiquan-
titative scoring. All 25 fields of the left lung at 20 view were
examined for each sample. Assessment of histological lung
injury was performed by grading as follows: infiltration or
aggregation of inflammatory cells in air space or vessel wall:
1 	 only wall, 2 	 few cells (1–5 cells) in air space, 3 	
intermediate, 4 	 severe (air space congested); interstitial
congestion and hyaline membrane formation: 1 	 normal
lung, 2 	 moderate (
25% of lung section), 3 	 intermedi-
ate (25–50% of lung section), 4 	 severe (50% of lung
section); hemorrhage: 0 	 absent, 1 	 present.
Forkhead box protein 3 (FoxP3) immunohistology
For immunohistochemistry, sections were dewaxed in xylene
and rehydrated in descending ethanol series. Antigen re-
trieval was performed in a decloaker in citrate-based antigen
unmasking solution (Vector Laboratories, Burlingame, CA,
USA) for 20 min at 125°C, followed by washing in TBS. Tissue
was permeabilized with 0.05% Tween in TBS for 5 min and
blocked in serum with 0.05% Tween for 60 min (Vectastain
Elite ABC Kit; Vector Laboratories). Sections were incubated
overnight at 4°C with primary antibody (Abcam 54501; Ab-
cam, Cambridge, MA, USA; dilution 1:1000 in TBS with 1%
serum). Slides were incubated in biotinylated secondary
antibody with 1% serum (Vectastein Elite ABC Kit) and
Vectastain Elite ABC reagent for 30 min, each. DAB was
prepared according to manufacturer’s instructions and ap-
plied for 45 s (DAB peroxidase substrate kit, Vector Labora-
tories). Counterstain was performed with methyl green for 30
s (Vector Methyl Green; Vector Laboratories). Sections were
photographed with a Nikon DS-U2/L2 (Nikon Instruments,
Melville, NY, USA). FoxP3 cell counts were performed at
20 view on 9 individual photographs per slide using NIS-
Element BR (Nikon Instruments).
Flow cytometry analysis
The cell pellet from BALF was obtained after spinning the
vials for 5 min at 400 g. The cell pellet, left lung, and spleen
were kept in RPMI until staining. Tissue was mechanically
disrupted, followed by 1 h incubation of tissue with collage-
nase D (Roche Diagnostics, Indianapolis, IN, USA) at a final
concentration of 1 mg/ml at 37°C. The homogenate was
forced through a 100-m mesh using the plunger of a 3-ml
syringe and washed. The following anti-mouse antibodies,
including clone name and fluorophore, were purchased from
eBioscience unless otherwise noted: CD73 (eBioTY/11.8,
PE), CD45 (30-F11, APC-eFluor780), major histocompatibility
complex II (MHCII; M5/114.15.2, PerCP; Biolegend, San
Diego, CA, USA), Ly6C (HK1.4, PerCP-Cy5.5), Ly6G (1A8,
PE-Cy7; BD Pharmingen, San Jose, CA, USA), CD4 (RM4-5,
AlexaFluor700), T-cell receptor- (TCR; H57-597, FITC),
and CD11b (M1/70, eFluor450). Cell suspension or dis-
rupted tissue was stained with a cocktail of antibodies con-
taining Fc block (2.4G2) for 30 min at room temperature in
the dark. For intracellular FoxP3 staining (FJK-16s, AF647;
eBioscience), cells were treated with FoxP3 staining buffer
according to manufacturer’s instructions (FoxP3 fixation/
permeabilization concentrate and diluent, and permeabiliza-
tion buffer, 10; eBioscience). Stains included a viability dye
to identify viable cells (Live/Dead Fixable Aqua Dead Cell
Stain Kit; Invitrogen, Life Technologies, Grand Island, NY,
USA), and T cells were routinely identified as viable using this
dye. Flow cytometry was performed on an LSRII (BD Biosci-
ences, San Jose, CA, USA), with compensation done using
FACSDiva software (BD Biosciences).
CD4CD25 T-cell purification and adoptive transfer
T cells were purified from spleen and mesenteric and popli-
teal lymph nodes of mice, mechanically disrupted over a
100-m filter, and subjected to magnetic bead enrichment for
CD4 T cells using a CD4CD25 Treg isolation kit (Miltenyi
Biotec, Bergisch Gladbach, Germany). Enriched CD4CD25 T
cells were then counted and resuspended in saline. A cell
suspension containing 3.25 105 cells/50 l was retroorbitally
injected into B6.Rag1/ mice anesthetized with pentobar-
bital (70 mg/kg). Intratracheal LPS application was per-
formed 14 h post-T-cell injection. Animals were euthanized 7
d post-LPS treatment.
In vitro regulatory CD4 T-cell differentiation assay
Naive CD4 T cells (CD4CD25) were isolated from
cd73/ or cd73/ spleen and peripheral lymph nodes as
described above and cultured in RPMI containing 10% fetal
bovine serum (FBS), 1% pencillin-streptomycin, 1% l-glu-
tamine, and -mercaptoethanol (50 M). Cells were treated
with recombinant IL-2 (10 ng/ml; eBioscience) alone (TH0
condition) or were cultured in the presence of a Treg
differentiating cytokine cocktail: rmIL-2 (10 ng/ml; eBiosci-
ence), rh-TGF-1 (5 ng/ml; eBioscience), all-trans retinoic
acid (100 M), anti-mIFN (XMG1.2; 10 g/ml, eBiosci-
ence), anti-mIL-4 (11B11; 10 g/ml, BioXCell, West Leba-
non, NH, USA), and anti-CD3/anti-CD28 microbeads (Dyna-
beads Mouse T-Activator CD3/CD28; Invitrogen). After 4 d,
cells were harvested and incubated with fluorescently labeled
antibodies against CD4 (RM4-5), CD25 (PC61.5), FoxP3
(FJK-16s), CLTA4 (UC10-4B9), and GITR (DTA-1, eBiosci-
ence). Live cells were discriminated with the use of Aqua
fluorescence reactive dye (Invitrogen). Flow cytometry anal-
ysis was performed using a BD FACSCanto (BD Biosciences).
In vitro macrophage suppression assay
Cd73/ alveolar macrophages were harvested by flushing
the airways with a total of 4 ml prewarmed PBS supplemented
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with 0.5 mM EDTA. BALF from 7 mice/strain was collected
and centrifuged for 10 min at 400 g at 4°C. Cells were
resuspended in 1 ml RPMI containing 10% FBS, 1% pencillin-
streptomycin, and 1% glutamine. Alveolar macrophages and
CD4CD25 T cells were seeded on a 96-well plate in a 2:1
ratio. Macrophages or CD4CD25 cells alone or in cocul-
ture were stimulated with 1 g LPS/ml supernatant or
medium as control. Supernatants were harvested after 20 h.
TNF- and IL-10 levels were determined with ELISA.
T-cell suppression assay
Measurement of Treg suppressive function was performed as
described previously (36). Briefly, CD4CD25 Tregs were
isolated by negative selection of CD4 T cells, followed by
positive selection of CD25 cells using the MACS Treg
isolation kit (Miltenyi Biotec). CellTrace Violet-labeled (In-
vitrogen) CD4CD25 effector T cells (50,000 cells/well)
were stimulated with anti-CD3 (1 g/ml) mAb in the pres-
ence of irradiated syngeneic CD90 antigen-presenting cells
and varying ratios of purified CD4CD25 Tregs from
cd73/ or cd73/ mice. Percentage suppression of prolif-
eration was determined by the CellTrace profile of dividing
effector cells at 72 h.
Software and statistical analysis
Data analysis and plotting were done using Prism 4.0c
(GraphPad Software, San Diego, CA, USA). Statistical analy-
ses were performed with unpaired t test, 1-way ANOVA, or
2-way ANOVA and Bonferroni’s multiple comparison posttest
correction as indicated. All data are expressed as means se.
Real-time PCR data were evaluated using SDS 2.3 (Applied
Biosystems). Flow cytometric data were analyzed using FlowJo
(TreeStar, Ashland, OR, USA).
RESULTS
Pharmacologic deprivation of adenosine by
administration of PEG-ADA impairs ALI resolution
Previous studies had demonstrated a functional role of
endogenously generated adenosine in attenuating acute
inflammatory events (2). To address the functional role of
extracellular adenosine in ALI resolution, we established
a murine model of LPS-induced lung injury/resolution
utilizing intratracheal LPS followed by 14 d recovery. To
probe the functional role of extracellular adenosine in
this ALI resolution mode, we first utilized treatment with
PEG-ADA to degrade extracellular adenosine in the lung.
ADA rapidly converts extracellular adenosine to inosine
and thereby effectively terminates extracellular adenos-
ine-signaling events (37). Based on previous studies exam-
ining different treatment regimens, and their effect on
extracellular adenosine levels (18), we treated intraperi-
toneally with 10 U PEG-ADA 3 d before LPS instillation,
immediately after intratracheal LPS treatment, and on d 7
post-LPS treatment (Fig. 1A). Indeed, LPS treatment was
associated with a time-dependent weight loss (2-way
ANOVA, P
0.0001). Consistent with our hypothesis that
endogenous adenosine functions to promote ALI resolu-
tion, we observed a more dramatic weight loss and failure
to recover in mice treated with PEG-ADA (2-way ANOVA,
P
0.0001; Fig. 1B). Moreover, PEG-ADA-treated mice
experienced prolonged and significantly increased lung
inflammation during the resolution of ALI. As such,
alveolar leukocyte infiltration was dramatically increased
in the BALF at 3 d following LPS treatment in the
PEG-ADA LPS group (P
0.01; Fig. 1C). Similarly, pulmo-
nary MPO activity as a measure of phagocyte influx and
activation was increased significantly in pulmonary tissue
from PEG-ADA LPS mice (P
0.01; Fig. 1D). In addition,
PEG-ADA administration was associated with prolonged
and increased pulmonary barrier dysfunction. Albumin
content of the BALF was considerably increased at 3 d
following LPS treatment (P
0.05; Fig. 1E).
Mice with a genetic defect in extracellular adenosine
generation (cd73/ mice) fail to resolve
LPS-induced ALI
After demonstrating that endogenous adenosine produc-
tion contributes to ALI resolution, we next utilized ge-
netic models to investigate the functional role of endog-
enous adenosine production and signaling during ALI
resolution. We have previously demonstrated that extra-
cellular adenosine production during ALI is controlled by
CD73, the terminal enzyme catalyzing extracellular con-
version of AMP to adenosine (6, 7, 24). For example,
adenosine measurements in wild-type mice exposed to
ventilator-induced lung injury showed dramatic increases
in their adenosine levels. This endogenous increase of
adenosine with ALI was completely blunted in cd73/
mice (7). Therefore, we felt confident that we could
utilize cd73/ mice as a genetic model to address the
functional role of extracellular adenosine production
during ALI. We compared the response of cd73/ and
cd73/ mice to LPS-induced lung injury resolution. We
found that cd73/mice experienced dramatic problems to
resolve LPS-induced inflammation. As depicted in Fig. 2A,
an LPS concentration of 1.875 g/g body weight
induced a transient weight loss in both genotypes, as
confirmed by 2-way ANOVA (P
0.0001). However,
cd73/ mice exhibited higher weight loss compared
with cd73/ mice between d 2 and 14 (2-way ANOVA,
P
0.0001). Moreover, treatment with a higher LPS
dose was associated with increased mortality of cd73/
mice. The cd73/ mice treated with a high LPS dosing
regimen (3.75 g/g body weight) demonstrated signif-
icantly aggravated weight loss (2-way ANOVA,
P
0.0001; data not shown) with 40% of the mice
succumbing within the observation period. None of the
cd73/ mice died (log-rank Mantel-Cox test, P
0.05
vs. cd73/ mice; Fig. 2B). Similarly to the above studies
in mice treated with PEG-ADA, cd73/ mice failed to
control lung inflammation and to adequately resolve
ALI. At 3 d after intratracheal administration of LPS,
leukocyte numbers in BALF from cd73/ mice signif-
icantly exceeded those determined in cd73/ mice
(P
0.01; Fig. 2C). Furthermore, lung injury scores in
histological sections of cd73/ mice compared with
controls revealed significantly increased ALI at d 3 and
14, indicating a failure of cd73/ mice to resolve ALI
(Fig. 2D). This is also displayed in H&E staining from
lung tissue depicting increased abundance of inflam-
matory cells in cd73/-deficient lungs. At 14 d after
the LPS insult, tissue sections from cd73/ mice re-
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sembled those from previously untreated mice (0 d),
whereas in sections from cd73/ mice lung injury was
not resolved, still demonstrating signs of injury with
interstitial infiltrates and cellular infiltration into the
air space. Also, genetic deletion of cd73 was associated
with increased mRNA expression of proinflammatory
mediators (Fig. 3) at 3 d after LPS administration, as
shown for TNF- (P
0.001), IL-1 (P
0.01), and IL-6
(P
0.001). Taken together, these genetic studies dem-
onstrate that CD73-dependent production of extracel-
lular adenosine plays a functional role for promoting
ALI resolution.
5=-NT reconstitution reduces pulmonary injury in
cd73/ mice
To affirm that the observed phenotype of cd73/ mice
was caused by a lack in extracellular adenosine generation
from precursor nucleotides, we pursued reconstitution in
these cd73/ mice. As we have done in previous studies,
we utilized soluble nucleotidase (5=-NT) derived from
snake venom for this purpose (7, 24, 30–32, 38). In the
line of these studies, we provided cd73/ mice with daily
injections of 5=-NT after LPS administration. 5=-NT aug-
ments adenosine levels by catalyzing the dephosphoryla-
tion of 5=-AMP to adenosine. In accordance with the
previous weight curve, weight reduction in cd73/ mice
was more pronounced compared with cd73/ mice
(2-way ANOVA, P
0.0001; Fig. 4A). Comparison of LPS
cd73/ groups revealed a significant acceleration of
weight recovery in animals that received 5=-NT reconsti-
tution compared with vehicle control (2-way ANOVA,
P
0.0001). Determination of cellular infiltrates and albu-
min leakage into BALF on d 3 post-LPS treatment dem-
onstrated less barrier disruption in 5=-NT-treated mice
(Fig. 4B, C). Only cd73/ vehicle mice exhibited signif-
icantly increased albumin levels compared with baseline
values (P
0.05) but not cd73/ or cd73/ 5=-NT
groups. In line with this observation, leukocyte numbers
in the BALF were highest in cd73/ vehicle mice
(P
0.05 vs. non-LPS group) whereas cell counts in 5=-NT-
treated cd73/ were not different from wild-type LPS
mice and did not reach the level of significance compared
with non-LPS-treated mice. Also, we observed reconstitu-
tion of a wild-type response when assessing lung injury
scores (Fig. 5B). This is also displayed in representative
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Figure 1. Enhanced adenosine turnover following PEG-ADA treatment aggravates weight loss and inflammation following
LPS-induced lung injury. A) Mice received 10 U PEG-ADA or vehicle 3 d before and immediately after LPS instillation; tissue
was harvested 3 d later. Mice included in the weight curve study were injected again after 7 d. B) Relative weight loss after LPS
treatment (3.75 g LPS/g body weight) in vehicle and PEG-ADA-treated wild-type mice. P values at indicated time points derived
from Bonferroni post hoc testing (n	10–11/group). C) BALF derived from PEG-ADA group 3 d after LPS application contains
higher leukocyte numbers (n	11–12/group). D) Pulmonary lysates from PEG-ADA-treated mice exhibit higher MPO activity
(n	6–10/group). E) Increased albumin content in BALF from PEG-ADA mice harvested on d 3 post-LPS treatment
(n	5–6/group).
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Figure 2. Lack of CD73 increases weight loss and enhances inflammation following intratracheal LPS instillation. A) Relative
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tissue section of the different treatment groups (Fig. 5A).
Taken together, these studies demonstrate that impaired
resolution of ALI observed in cd73/ mice can be
rescued by treatment with soluble nucleotidase, thereby
highlighting the functional role of extracellular adeno-
sine production in promoting ALI resolution.
CD73high Tregs promote ALI resolution
Previous studies had shown that Tregs play a key role in
ALI resolution (33), while other studies demonstrate that
Treg-dependent immune functions are linked to CD73
expression and CD73-dependent adenosine production
(29). To examine the functional role of CD73 in the
immunological response to ALI, we determined CD73
expression on BAL cells 6 d following ALI initiation.
Interestingly, we observed that Tregs possess exceptionally
high CD73 levels (P
0.001; Fig. 6A). We and others
detected Tregs in the alveolar compartment as early as
24–48 h after exposure to intratracheal LPS (33, 39).
However, we found the maximum number of Tregs after
7 d following the LPS insult. To exclude the assumption
that cd73/ mice possess less Tregs, we performed
fluorescence activated cell sorting which did not show a
difference in Treg numbers between the strains (Fig. 6B).
In contrast, anti-inflammatory IL-10 secretion into BALF
was significantly attenuated in cd73/ mice on d 6
(P
0.05; Fig. 6C). Next, we harvested CD4CD25T cells
from spleen and lymph nodes and characterized the
cd73/ and cd73/ Treg populations. Based on our
previous observations in BALF, we confirmed that splenic
CD4 Tregs are the highest expressers of CD73 (Fig. 7A).
Next, a Treg differentiation assay of cd73/ and cd73/
CD4CD25 T cells was performed, and the abundance
of FoxP3 Tregs was detected (Fig. 7B). In line with the
comparable Treg frequencies measured in vivo, CD73
expression did not have any developmental influence on
the amount of differentiated Tregs. Glucocorticoid-in-
duced TNFR-related (GITR), cytotoxic T-lymphocyte an-
tigen 4 (CTLA4), CD25, and FoxP3 are proteins charac-
teristically expressed by Tregs. The cd73/ and cd73/
Tregs showed equal expression levels of these (Fig. 7C).
Due to the fact that Tregs are known to express TLR4 and
directly respond to LPS (40, 41), we examined cd73/
and cd73/ CD4CD25 cells in culture, stimulated
them with LPS for 24 h, and measured TNF- and IL-10 in
the supernatant (Fig. 7D). Interestingly, cd73/ cells
secreted significantly more TNF- (P
0.001) but less
IL-10 (P
0.001) into the medium, suggesting an anti-
inflammatory phenotype dependent on functional CD73.
In further experiments, we tested whether CD73 expres-
sion on Tregs influences TNF secretion in coculture with
cd73/ macrophages. Here we observed that the pres-
ence of cd73/ Tregs significantly failed to limit the
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expression of TNF- in the medium (P
0.001; Fig. 7E).
Furthermore, lack of cd73 decreased the suppressive func-
tion of Tregs on the proliferation of effector T cells (Fig. 7F).
Suppressor function differed significantly at 1:1 to 1:4 ratios
of Tregs to cd73/ responding T cells. Studies were addi-
tionally performed using cd73/ responder T cells with
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comparable results. Together, these studies demonstrate
that while cd73/mice have similar numbers of Tregs, their
immune-suppressive function is significantly attenuated.
Adoptive transfer of cd73/ but not cd73/ Tregs
mediates the resolution of lung injury in B6.Rag1/ mice
To address the functional role of Treg-dependent CD73
during ALI, we next performed adoptive transfer studies.
For this purpose, CD4CD25 T cells separated from
spleen and lymph node suspensions enriched for Tregs
were retroorbitally injected into B6.Rag1/ mice at
equal cell numbers 14 h before intratracheal LPS stimu-
lation (Fig. 8A). BALF was collected 7 d later, and
leukocyte numbers were counted (Fig. 8B). Lavage from
mice receiving cd73/ Tregs contained significantly
more leukocytes (P
0.05; Fig. 8B). In line with the
above-mentioned in vitro studies, IL-10 protein secretion
was maximal in those mice injected with cd73/ Tregs
(P
0.05; Fig. 8C). Lung injury scoring reflected these
results, and histology revealed a progressive resolution in
mice receiving cd73/ Tregs compared with cd73/
Tregs (P
0.05; Fig. 8D, E). To exclude any suspicion that
these results were based on differing survival of Tregs, we
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stained for FoxP3 and counted the positive cells. Evalua-
tion demonstrated no differences in the recovery of cells
7 d after adoptive transfer and LPS treatment (cd73/ vs.
cd73/ Tregs: 65.447.697 vs. 72.982.109 cells per
photograph; 9 photographs/slide from n	5 mice/group;
Fig. 8F). Taken together, these studies implicate a crucial
role for Treg-dependent CD73 in ALI resolution.
DISCUSSION
During the course of an acute inflammatory event, endog-
enous signaling pathways determine the outcome and
progression of the disease process. Activation of these
pathways can result in the development of chronicity,
fibrosis, and organ dysfunction. However, more com-
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monly, an inflammatory insult will resolve toward its
resolution, promote healing, and establish normal organ
function (2, 42). Here, we hypothesized that the endog-
enous generation of adenosine is central to inflammatory
resolution of lung inflammation following ALI. In sup-
port of this hypothesis, our studies demonstrated that
recovery from LPS-induced lung injury was significantly
impaired in mice treated with PEG-ADA at levels well
above those that have been shown to lower adenosine
concentrations in the lung following injury (43–45). The
association between pharmacologic inactivation of extra-
cellular adenosine and diminished recovery from ALI
provides the first evidence for a functional role of extra-
cellular adenosine in ALI resolution. As a second step, we
performed studies in cd73/ gene-targeted mice, which
are characterized by their inability to generate extracellu-
lar adenosine from precursor nucleotides. These studies
provide the first genetic evidence that cd73 deficiency is
associated with a profound failure to adequately resolve
ALI. Expressional studies of CD73 on inflammatory cells
trafficking to the lung during ALI resolution revealed
high levels of CD73 expression on Tregs. Indeed, a
combination of in vitro studies examining cd73-deficient
Tregs and in vivo studies of adoptive transfer of wild-type
or cd73/ Tregs revealed a functional role of Treg-
dependent CD73 in ALI resolution.
The present studies implicating CD73-dependent aden-
osine production in ALI are consistent with previous
studies showing a functional role of CD73 during the
acute phase of ALI. For example, we previously demon-
strated that cd73 deficiency is associated with an enhanced
acute inflammatory response during bleomycin-induced
lung injury (46). Similarly, studies of ventilator-induced
lung injury or lung injury induced by LPS inhalation
indicated a more profound early inflammatory phase in
cd73/ mice compared with control animals (2, 7).
However, during chronic disease states, extracellular
adenosine signaling can become detrimental (47–50). For
example, mice with genetic deletion of ADA and concom-
itant elevations of extracellular adenosine suffer from a
chronic form of lung disease (43). Extensions of these
studies revealed that while extracellular adenosine signal-
ing is lung protective during the early onset of inflamma-
tion, adenosine signaling can become detrimental once
chronicity has developed (49). However, the present
studies suggest that during inflammatory lung disease, as
opposed to established pulmonary fibrosis or chronic
obstructive lung disease, adenosine signaling can prevent
the development of disease chronicity by enhancing Treg
functions and Treg-dependent ALI resolution.
Previous studies have implicated extracellular aden-
osine signaling in modulating immune functions of
inflammatory cells from the innate or the adoptive
immune system. For example, the first pharmacologic
studies to implicate adenosine signaling in attenuating
inflammatory cell activation come from the laboratory
of Cronstein (51). A landmark study from Ohta and
Sitkovsky (21) provided genetic evidence that an indi-
vidual adenosine receptor, the A2aR, plays a critical
part of the physiological negative feedback mechanism
for limitation and termination of both tissue-specific
and systemic inflammatory responses. The A2aR-medi-
ated lung tissue protection was further approved by
Thiel et al. (52) who demonstrated that deleterious side
effects of high oxygen treatment in acute respiratory
distress syndrome were overcome by selective A2aR
agonist application. Other studies implicate the aden-
osine signaling in attenuating TNF release from neu-
trophils during inflammatory disease (53) or on den-
dritic cells during ischemia and reperfusion injury (54).
Also, adenosine generation and signaling have been
implicated in T-cell functions, for example, by inhibit-
ing inflammatory activation of CD4-T cells (55, 56). A
recent study elucidated that CD4CD73 T cells may
contribute to HIV-1 pathogenesis since this T-cell sub-
set was depleted in HIV-1-infected patients, correlating
inversely with T-cell activation (57). Furthermore,
adenosine enhances the immunosuppressive functions
of Tregs (29, 39). These later findings are consistent
with the results from our present studies implicating
adenosine generation on Tregs in promoting ALI res-
olution. Indeed, ALI resolution has been closely linked
to functional Tregs (33).
Previous studies have demonstrated a transcription-
ally regulated pathway for CD73 that is under the
control of the transcription factor hypoxia-inducible
factor (HIF). Inflammatory diseases of the mucosa,
such as inflammatory bowel disease or during ALI, are
characterized by an alteration of the balance between
oxygen demand and supply, thereby resulting in pro-
found tissue hypoxia (1, 12). Indeed, the interdepen-
dent relationship between hypoxia and inflammation
during inflammatory diseases of the mucosa results in
the activation of hypoxia-dependent transcriptional
pathways, including HIF (51–55). As such, previous
studies utilizing ambient hypoxia exposure of epithelial
cells demonstrated robust induction of CD73 tran-
script, protein and function with hypoxia. Moreover,
studies with CD73 promoter constructs, HIF loss of
function, and transcription factor binding assays dem-
onstrated that HIF controls the hypoxic induction of
CD73 (27). In addition, cd73/ mice are more prone
to hypoxia-associated vascular dysfunction (24) and
hypoxia-driven inflammation (25). Hypoxia within in-
flamed areas of the lungs could represent a stimulus for
CD73 induction and enhanced adenosine production
and previous studies from the laboratory of Sitkovsky
(52, 58) have implicated hypoxia in enhancing adeno-
sine responses during ALI, and concomitant protection
from bacterial ALI. Furthermore, recent studies indi-
cate that hypoxia can directly impact Treg differentia-
tion via HIF-dependent induction of FoxP3 and con-
comitant Treg expansion (59).
Taken together, the present studies define a fundamen-
tal role for CD73-dependent adenosine production in ALI
resolution. These studies implicate Treg expression of
CD73 as a central contributor to endogenous lung pro-
tection. Ultimately, these observations provide a number
of therapeutic opportunities. Future challenges will in-
clude hurdles to translating these experimental findings
from the laboratory into novel therapeutic treatment
modalities, for example, by defining clinical strategies to
enhance Treg functions during ALI or to target adeno-
sine signaling to promote ALI resolution in patients.
Prospective studies may rule out time-dependent activa-
tion and contribution of A2aR and A2bR to adenosine-
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mediated lung protection and resolution of injury, thereby
providing further therapeutic applications through selective
agonist treatment.
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